SPLIT			
$sitecode	User:	System Date:	Mode: Development
Site Name:			

Demographics (DEM)

Version: 5.0; 11-30-07

1. Namecode: *(NAMECODE)*
2. Date of birth: *(REGDTBIR)* *(mm/dd/yyyy)*
3. Ethnicity: *(REGETHNI)*

   Hispanic or Latino - 1
   Not Hispanic or Latino - 2
   Not Reported - 0
4. Race:

   Not Reported: *(REGNOREP)*

   Select the appropriate race(s) according to the descriptions provided in the Forms Instructions.

   a. Asian: *(REGASIAN)* No - 0 Yes - 1

   b. Black or African American: *(REGBLACK)* No - 0 Yes - 1

   c. Native Alaskan or American Indian: *(REGNATIV)* No - 0 Yes - 1

   d. Native Hawaiian or other Pacific Islander: *(REGHAWII)* No - 0 Yes - 1

   e. White or Caucasian: *(REGWHITE)* No - 0 Yes - 1
5. Sex: *(REGSEX)* Male - 1 Female - 2
6. Blood type: *(REGBLOOD)*

   A - 1
   B - 2
   O - 3
   AB - 4
7. Primary liver disease diagnosis following evaluation: *(REGPRDIS)*

   1.01- Biliary atresia
   1.02- Alagille's syndrome
   1.04- Byler's disease and Familial cholestasis/ cirrhosis
   1.05- Idiopathic cholestasis/ cirrhosis
   1.07- TPN induced
   *Additional Options Listed Below

   If *Other* selected for any sub group, please specify: *(REGAGOTH)*

   If 1.01-Biliary Atresia selected for primary diagnosis answer the following:

   Is the participant enrolled in BARC (Biliary Atresia Research Consortium)? *(PTINBARC)* No - 0 Yes - 1

   If yes, what is the 7 digit BARC ID? *(BARCID)*
8. Date consent/assent or data authorization *(mm/dd/yyyy)* obtained: (CONSDATE)

Additional Selection Options for DEM

Primary liver disease diagnosis following evaluation:

1.08- Primary sclerosing cholangitis
1.09- Biliary strictures
1.10- Neonatal hepatitis
1.99- Other cholestatic
2.01- Acute hepatitis A
2.02- Acute hepatitis B
2.03- Acute hepatitis C
2.04- Subacute hepatitis A
2.05- Subacute hepatitis B
2.06- Subacute hepatitis C
2.07- Fulminant liver failure unknown etiology
2.08- Fulminant autoimmune hepatitis
2.09- Subacute fulminant liver failure
2.99- Other fulminant liver failure
3.01- Alpha1- Antitrypsin deficiency
3.02- Wilson's disease
3.03- Tyrosinemia
3.04- Primary hyper oxaluria
3.05- Cystic fibrosis
3.06- Urea cycle defects
3.07- Crigler- Najjar
3.08- Glycogen storage disease
3.09- Neonatal hemachromatosis
3.10- Inborn error in bile acid metabolism
3.99- Other metabolic disease
4.01- Hepatocellular carcinoma
4.02- Hepatoblastoma
4.03- Hemangioendothelioma
4.99- Other tumor
5.01- Accidental overdose
5.02- Attempted suicide
5.03- Drug induced
5.99- Other toxicity
6.01- Cirrhosis due to neonatal hepatitis
6.03- Cirrhosis due to hepatitis B
6.04- Cirrhosis due to hepatitis C
6.05- Cirrhosis due to autoimmune hepatitis
6.06- Cirrhosis due to unknown cause
6.99- Cirrhosis due to other
7.01- Budd-Chiari syndrome
7.02- Congenital hepatic fibrosis
9.99- Other